MECHANISMS OF SIGNAL TRANSDUCTION
Heme Oxygenase-1-derived Carbon Monoxide Requires the Activation of Transcription Factor NF-κB to Protect Endothelial Cells from Tumor Necrosis Factor-α-mediated Apoptosis*

https://doi.org/10.1074/jbc.M108317200Get rights and content
Under a Creative Commons license
open access

We have shown that carbon monoxide (CO) generated by heme oxygenase-1 (HO-1) protects endothelial cells (EC) from tumor necrosis α (TNF-α)-mediated apoptosis. This effect relies on the activation of p38 MAPK. We now demonstrate that HO-1/CO requires the activation of the transcription factor NF-κB to exert this anti-apoptotic effect. Our data suggest that EC have basal levels of NF-κB activity that sustain the expression of NF-κB-dependent anti-apoptotic genes required to support the anti-apoptotic effect of HO-1/CO. Over-expression of the inhibitor of NF-κB α (IκBα) suppresses the anti-apoptotic action of HO-1/CO. Reconstitution of NF-κB activity, by co-expression of IκBα with different members of the NF-κB family, i.e. p65/RelA or p65/RelA plus c-Rel, restores the anti-apoptotic effect of HO-1/CO. Expression of the NF-κB family members p65/RelA or p65/RelA with p50 or c-Rel up-regulates the expression of the anti-apoptotic genes A1, A20, c-IAP2, and manganese superoxide dismutase (MnSOD). Inhibition of NF-κB activity by over-expression of IκBα suppresses the expression of some of these anti-apoptotic genes, i.e. c-IAP2. Under inhibition of NF-κB, co-expression of some of these anti-apoptotic genes, i.e. c-IAP2 and A1, restores the anti-apoptotic action of HO-1/CO, whereas expression of A20 or MnSOD cannot. The ability of c-IAP2 and/or A1 to restore the anti-apoptotic action of HO-1/CO is abolished when p38 MAPK activation is blocked by over-expression of a p38 MAPK dominant negative mutant. In conclusion, we demonstrate that HO-1/CO cooperates with NF-κB-dependent anti-apoptotic genes, i.e. c-IAP2 and A1, to protect EC from TNF-α-mediated apoptosis. This effect is dependent on the ability of HO-1/CO to activate the p38 MAPK signal transduction pathway.

Cited by (0)

Published, JBC Papers in Press, March 5, 2002, DOI 10.1074/jbc.M108317200

*

This work was supported in part by Grant 998521355 from the Roche Organ Transplantation Research Foundation and by National Institutes of Health Grants HL67040 (to M. P. S.) and HL58688 (to F. H. B.). The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked “advertisement” in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

§

Both authors contributed equally to this work.

Supported by a grant from Institut National de la Santéet de la Recherche Médicale (INSERM), France.

Supported by a fellowship of the Swiss National Science Foundation.

Supported by Grant BD2990/00 from the “Fundaçao para a Ciencia e Tecnologia” Portugal.

§§

The Lewis Thomas Professor at the Harvard Medical School and a paid consultant for Novartis Pharma.